Bausch Health vs TCS: Founders, CEOs and History
Bausch Health was founded in 1994 by Eugene Melnyk, Milan Panic and is led by Thomas J. Appio. TCS was founded in 1968 by J.R.D. Tata, F.C. Kohli and is led by K Krithivasan.
Company facts
Bausch Health
- Founded
- 1994
- Headquarters
- Laval, Quebec, Canada
- Current CEO
- Thomas J. Appio
- Employees
- 20,300
TCS
- Founded
- 1968
- Headquarters
- Mumbai, Maharashtra, India
- Current CEO
- K Krithivasan
- Employees
- 593,798
Founders
Bausch Health
Eugene Melnyk
Eugene Melnyk built Biovail into Canada's largest publicly traded pharmaceutical company, with revenue growing from about $19M in 1995 to roughly $1.07B in 2006.
Milan Panic
Milan Panic ran ICN Pharmaceuticals for four decades and made it known for the broad-spectrum antiviral ribavirin, sold as Virazole.
TCS
J.R.D. Tata
J.R.D. Tata was chairman of Tata Sons from 1938 to 1991. Under his leadership the group set up Tata Computer Centre in 1968, which became Tata Consultancy Services, initially to provide data-processing and management-consultancy services to Tata companies.
F.C. Kohli
Faqir Chand Kohli (1924-2020) moved from Tata Electric Companies to lead TCS in 1969 and served as its first general manager and later CEO until 1996.
CEOs and their tenures
Bausch Health
- J. Michael Pearson2008–2016
Former Chief Executive Officer
Pearson, a former McKinsey director, became chief executive of Valeant Pharmaceuticals effective February 1, 2008 and ran the company through the September 2010 merger with Canada's Biovail until early May 2016.
Source - Joseph C. Papa2016–2022
Former Chief Executive Officer
Papa, previously chief executive of Perrigo, was named chairman and CEO in April 2016 and took over in early May 2016, inheriting about $30B of debt, an SEC investigation and congressional scrutiny of Valeant-era drug pricing.
Source - Thomas J. Appio2022–present
Chief Executive Officer
Appio became chief executive officer and a director in May 2022, succeeding Joseph Papa.
Source
TCS
- F. C. Kohli1969–1996
Co-founder and First CEO
By the time Kohli stepped down from executive responsibility in 1996, TCS-trained programmers numbered in the hundreds of thousands and had helped launch India's broader IT-export industry, earning Kohli the title 'Father of the Indian IT Industry' and India's…
Source - N. Chandrasekaran2009–2017
CEO
He became chairman of Tata Sons in February 2017 and also chairs TCS's board and Air India.
Source - Rajesh Gopinathan2017–2023
CEO and Managing Director
Under Gopinathan, TCS shares nearly tripled, revenue almost doubled, and profit rose about 60% over his six-year tenure -- one of the strongest CEO track records in Indian corporate history.
Source - K. Krithivasan2023–present
CEO and Managing Director
Under Krithivasan, TCS crossed $30 billion in annual revenue in FY2026 and grew its annualized AI revenue run rate to $2.6 billion by Q1 FY2027, even as dollar revenue was roughly flat amid weak discretionary IT spending.
Source
Timeline: Bausch Health and TCS side by side
1959Bausch Health
Milan Panic founds ICN Pharmaceuticals
Milan Panic, a Yugoslav immigrant to California, founded ICN Pharmaceuticals in 1959 and ran it for four decades. ICN is the predecessor of Valeant Pharmaceuticals and of today's Bausch Health.
1968TCS
TCS is founded
Tata Consultancy Services begins inside the Tata Group.
1969TCS
F.C. Kohli Joins as First CEO
F.C. Kohli is brought in on deputation to lead TCS, then a 10-consultant operation, and begins building an industrial, assembly-line approach to software delivery.
1994Bausch Health
Biovail Corporation International formed in Canada
On March 29, 1994 Eugene Melnyk consolidated his Canadian drug-delivery business by amalgamating Trimel Corporation with its subsidiary to create Biovail Corporation International, the legal entity that files today as Bausch Health Companies Inc.
2001TCS
CMC Limited Stake Acquired
TCS acquires a majority stake in CMC Limited from the Government of India, adding systems-integration and public-sector technology capability.
2001TCS
TCS Crosses $1 Billion in Revenue
TCS becomes the first Indian IT services company to cross $1 billion in annual revenue, cementing its position as an industry leader.
2003Bausch Health
ICN renames itself Valeant Pharmaceuticals
ICN Pharmaceuticals, then based in Costa Mesa, California, took the Valeant Pharmaceuticals name in November 2003 to distance itself from the governance fights of the Panic era.
2004TCS
TCS lists publicly
TCS completes its IPO and becomes one of India's most important listed technology companies.
2008Bausch Health
J. Michael Pearson becomes chief executive
Valeant appointed former McKinsey director J. Michael Pearson as chief executive effective February 1, 2008, succeeding Timothy C. Tyson. Pearson replaced internal research spending with debt-funded acquisitions of marketed drugs.
2009TCS
TCS crosses major global scale thresholds
TCS expands globally across industries and delivery centers under new then-CEO N. Chandrasekaran.
2010Bausch Health
Biovail and Valeant complete their merger
The merger of Biovail Corporation and Valeant Pharmaceuticals International closed on September 28, 2010. The combined company kept the Valeant name and Pearson as chief executive but was incorporated in Canada.
2011Bausch Health
Ortho Dermatologics bought from Johnson and Johnson
Valeant agreed to acquire the U.S. Ortho Dermatologics assets from Janssen Pharmaceuticals, a Johnson and Johnson company, for about $345M in cash, building the dermatology franchise.
2013Bausch Health
Bausch + Lomb acquired for $8.7 billion
Valeant agreed in May 2013 to buy eye-health company Bausch + Lomb from Warburg Pincus for $8.7B in cash, adding contact lenses, lens care, ophthalmic drugs and surgical devices.
2013TCS
N. Chandrasekaran Becomes CEO
Chandrasekaran becomes CEO, leading TCS through a period of rapid international expansion before his 2017 elevation to Tata Sons chairman.
2015Bausch Health
Salix acquisition closes at about $11.1 billion
Valeant completed its tender offer for Salix Pharmaceuticals on April 1, 2015 at $173 per share, about $11.1B in equity value and roughly $15.8B including debt, gaining the Xifaxan franchise.
2015Bausch Health
Drug pricing and Philidor scandal breaks
Congressional investigators pressed Valeant over 525% and 212% increases on the heart drugs Isuprel and Nitropress, bought in February 2015, and over its undisclosed ties to the Philidor mail-order pharmacy.
2016Bausch Health
Joseph Papa replaces Pearson as chief executive
Valeant named Perrigo chief executive Joseph C. Papa as chairman and CEO on April 25, 2016, and he took over in early May 2016 with about $30B of debt outstanding.
2017Bausch Health
Skincare brands and Dendreon sold to cut debt
Valeant sold the CeraVe, AcneFree and AMBI skincare brands to L'Oreal for about $1.3B and the Dendreon cancer unit to China's Sanpower Group for about $820M, using the proceeds to repay debt.
2018Bausch Health
Company renamed Bausch Health Companies Inc.
The name change from Valeant Pharmaceuticals International, Inc. to Bausch Health Companies Inc. was completed on July 13, 2018, and the shares began trading as BHC on the NYSE and TSX on July 16, 2018.
2020Bausch Health
SEC settlement closes the Philidor accounting case
On July 31, 2020 Bausch Health agreed to pay a $45M civil penalty to settle SEC charges of improper revenue recognition and misleading disclosures tied to Philidor. Former chief executive J. Michael Pearson and two other executives also settled.
2020TCS
F.C. Kohli Passes Away
F.C. Kohli, TCS co-founder and first CEO, dies at age 96, having lived to see the company he helped build become one of the worlds largest IT services firms.
2022Bausch Health
Bausch + Lomb listed on the NYSE and TSX
Bausch + Lomb common stock began trading under the ticker BLCO on May 6, 2022, and a Bausch Health subsidiary sold 35,000,000 Bausch + Lomb shares in the offering. Bausch Health retained about 88% of the eye-health company and still consolidates it. Thomas J.
2023TCS
K. Krithivasan becomes CEO
K. Krithivasan becomes CEO and managing director of TCS, succeeding Rajesh Gopinathan.
2025Bausch Health
DURECT acquired and record annual revenue reported
Bausch Health closed the DURECT acquisition on September 11, 2025 for about $63M upfront, completed Solta Medical's Chinese aesthetics distribution purchase on December 1, 2025, and reported FY2025 revenue of $10.266B, up 7%, with net income attributable to Ba…
2026Bausch Health
RED-C trials miss endpoints and trigger a $1.4 billion charge
In January 2026 the two Phase 3 RED-C trials of amorphous-rifaximin soluble solid dispersion for primary prevention of hepatic encephalopathy missed their primary endpoints.
2026Bausch Health
Second-quarter 2026 revenue of $2.85 billion and raised guidance
Bausch Health reported second-quarter 2026 revenue of $2.85B, up 13%, net income attributable to Bausch Health of $258M and adjusted EBITDA of $1.075B, and raised its full-year 2026 revenue, adjusted EBITDA and cash flow guidance.
2026TCS
FY2026 revenue is reported
TCS reports FY2026 revenue of $30.017B and net margin of 19.8%.
2026TCS
Q1 FY2027 AI run-rate grows
TCS reports Q1 FY2027 revenue of $7.624B and annualized AI revenue of $2.6B.
2026TCS
Tata Sons chairman succession opens
On August 12, 2026, N. Chandrasekaran said he would not seek another term as Tata Sons chairman after February 2027; TCS shares fell about 4% on the news.
Acquisitions
Bausch Health
- DURECT Corporation2025$63M
- Shibo Zhenmei aesthetics distribution business2025Undisclosed
- Salix Pharmaceuticals2015$11.1B
- Bausch + Lomb Holdings2013$8.7B
- Ortho Dermatologics2011$345M
TCS
- W12 Studios2018Undisclosed
- Citigroup Global Services2008$505M
- CMC Limited2001Undisclosed
Questions about Bausch Health vs TCS
Who is the CEO of Bausch Health Companies Inc. and Tata Consultancy Services Limited?
Bausch Health Companies Inc. is led by Thomas J. Appio and Tata Consultancy Services Limited is led by K Krithivasan. Both serve as the top executive responsible for the company's strategy, operations, and financial performance.
When was Bausch Health Companies Inc. founded vs Tata Consultancy Services Limited?
Tata Consultancy Services Limited was founded in 1968 — 26 years before Bausch Health Companies Inc., which was founded in 1994. Tata Consultancy Services Limited's longer operating history gives it a deeper track record but also potentially more institutional inertia compared to the younger Bausch Health Companies Inc..
How many employees does Bausch Health Companies Inc. have compared to Tata Consultancy Services Limited?
Bausch Health Companies Inc. employs approximately 20,300 people, while Tata Consultancy Services Limited employs approximately 593,798. Tata Consultancy Services Limited has the larger workforce at 593,798 employees, compared to Bausch Health Companies Inc.'s 20,300. A higher headcount does not necessarily imply greater efficiency — it often reflects differences in business model (e.g., manufacturing vs. software).
Where are Bausch Health Companies Inc. and Tata Consultancy Services Limited headquartered?
Bausch Health Companies Inc. is headquartered in Canada and Tata Consultancy Services Limited is headquartered in India. Their different home markets mean they may face different regulatory frameworks, tax regimes, and currency exposure.
Who founded Bausch Health Companies Inc. and Tata Consultancy Services Limited?
Bausch Health Companies Inc. was founded by Eugene Melnyk, Milan Panic. Tata Consultancy Services Limited was founded by J.R.D. Tata, F.C. Kohli.
Which company has a longer operating history — Bausch Health Companies Inc. or Tata Consultancy Services Limited?
Tata Consultancy Services Limited has been operating for approximately 58 years, making it the more established of the two companies. Bausch Health Companies Inc. has been in operation for around 32 years. A longer operating history often signals greater institutional resilience and brand recognition, though it can also mean slower adaptation to new market conditions.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the Bausch Health vs TCS overview